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antibacterial ﬂuoroquinolones to antitumor ﬂuoroquinolones, a series of C3/C3 bis-ﬂuoroquino-
lone fused heterocycles cross-linked with a [1,2,4]-triazolo[3,4-b] [1,3,4]-thiadiazole core as a
common bioisostere of two carboxylic acid groups was designed and synthesized as their
hydrochloride salts. Structures were characterized by elemental analysis and spectral data and
their in vitro antitumor activity against L1210, CHO and HL60 cell lines was screened by
determination of their IC50 values in the methylthiazole trazolium (MTT) assay. Two compounds
were highly potent against the HL60 cell line and represent promising lead compounds for future
development.
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Recently, the shift from antibacterial ﬂuoroquinolones (ABFQs)
to antitumor ﬂuoroquinolones (ATFQs) based on their mechan-
istic similarities and sequence homologies of their target topoi-
somerases has received considerable attention1,2. Many ATFQs
have been derived by structural modiﬁcation of the clinical
ABFQs, especially in the heterocyclic ring such as piperazine at
the 7-position of the quinolone scaffold3–5, whereas only a few
of these have been produced by modiﬁcation of the carboxylic
acid group at the 3-position6,7. Unfortunately, the resultant
compounds were not considered worthy of clinical evaluation
due to issues with their in vitro toxicity, stability or bioavail-
ability. Therefore, there remains an urgent need to develop an
efﬁcient synthetic route for ATFQs to facilitate their evaluation
as therapeutic agents.
In recent reports, we have shown that it is not necessary for
an ATFQ to retain the C-3 carboxylic acid group and that some
ATFQs derived by isosteric replacement of the carboxylic acid
group with a (fused) heterocyclic ring such as oxadiazole or
s-triazolo[3,4-b] [1,3,4]thiadiazine display anticancer activity8. In
addition, a heterocyclic ring system related to s-triazolo[3,4-b]
[1,3,4]thiazole has been widely investigated9, but the use of aN
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Scheme 1 Synthetic route for the bis-ﬂuoroquinolones cross-linked wi
N-Methyl ciproﬂoxacin (2b); Enroﬂoxacin (2c); Norﬂoxacin (6a); Oﬂo
R1¼H, R3¼methyl, R2¼cyclopropyl (1b); R1¼H, R3¼ethyl, R2¼cy
R2¼cyclopropyl (1e); R1¼R3¼methyl, R2¼cyclopropyl (1f); R1¼
R2¼ethyl (1h); R1¼ethyl, R3¼H, R2¼cyclopropyl (1i); R1¼ethyl, R
(1k); R1¼ethyl, R3¼H, R2¼ethyl (1l); S/R-(7)–R1¼H (1m); S/R-(
S-(-)–R1¼methyl (1q); S-(-)–R1¼ethyl (1r).ﬂuoroquinolone scaffold as a substituent of the fused core at
both the 3- and 6-positions has not been attempted. In this
paper we report the synthesis from current antibacterial ﬂuoro-
quinolones of ﬁve 3,6-ﬂuoroquinolone-substituted [1,2,4]tria-
zolo[3,4-b] [1,3,4]thiadiazoles in which the fused heterocyclic
ring of triazolothiadiazole acts as a common bioisostere of the
two carboxylic acid groups (Scheme 1).2. Results and discussion
The intermediate ciproﬂoxacin hydrazide derivatives 3a–3c,
prepared from N-substituted ciproﬂoxacins 2a–2c according to
the known procedure10, were subjected to a cyclo-condensation
with carbon disulﬁde in the presence of excess alkali-ethanol
solution to yield the oxadiazole thiols 4a–4c. A convenient base-
catalyzed conversion of 4a–4e to the amino s-triazole thiols
5a–5c was carried out using hydrazine hydrate. Interestingly, the
condensation of 5a–5c with each of the commercially available
ABFQs (2a–2c and 6a–6c) to produce the target compounds
1a–1r was successful only in the presence of POCl3 and not in
the presence of other acidic media such as concentrated sulfuric
acid or polyphosphoric acid.N
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th [1,2,4]triazolo[3,4-b] [1,3,4]thiadiazole 1a–1r. Ciproﬂoxacin (2a);
xacin (6b); Levoﬂoxacin (6c). R1¼R3¼H, R2¼cyclopropyl (1a);
clopropyl (1c); R1¼R3¼H, R2¼ethyl (1d); R1¼methyl, R3¼H,
methyl, R3¼ethyl, R2¼cyclopropyl (1g); R1¼methyl, R3¼H,
3¼methyl, R2¼cyclopropyl (1j); R1¼R3¼ethyl, R2¼cyclopropyl
7)–R1¼methyl (1n); S/R-(7)–R1¼ethyl (1o); S-(-)–R1¼H (1p);
Table 1 Growth inhibitory activities (IC50 m mol/L) of
compounds (1a–1r) against L1210, HL60 and CHO tumor
cells in the MTT assay.
Compound IC50 (m mol/L)
L1210 HL60 CHO
1a 3.6 0.54 7.8
1b 8.5 5.3 11.6
1c 14.2 2.7 15.0
1d 18.5 10.6 17.2
1e 6.2 2.7 10.5
1f 12.4 8.8 15.7
1g 16.2 4.7 17.5
1h 21.3 15.4 22.6
1i 8.6 5.0 13.7
1j 14.6 10.6 17.8
1k 18.02 7.2 19.5
1l 23.6 18.4 26.2
1m 15.6 14.2 16.8
1n 17.2 16.8 21.4
1o 18.0 16.4 23.7
1p 1.5 0.12 3.4
1q 2.7 1.8 5.2
1r 2.5 2.0 3.8
Guo-qiang Hu et al.174Being asymmetrical, the 1H NMR spectra of compounds
1a–1r displayed one two-proton singlet signal at d 9.20–8.90
assignable to the 2-H of the ﬂuoroquinolone scaffold; other
protons such as the 5-H and 7-piperazine-H or 8-H are in close
accord with their corresponding parent ﬂuoroquinolone car-
boxylic acids11. In addition, the chemical shift for all target
compounds 1a–1r at d 11.0–12.0 (exchangeable with D2O)
indicates the presence of dihydrochloride salts and the mole-
cular ion peaks show a base peak in the MS spectrum
corresponding to the respective molecular formulae of the
free bases.
The in vitro antitumor activities of 1a–1r against murine
leukemia cell line (L1210), human leukocytoma cell line
(HL60) and Chinese hamster ovary cell line (CHO) were
evaluated using the MTT assay12 (Table 1). Interestingly, the
results reveal that all compounds show cytotoxicity with IC50
values in the range 0.12–26.2 mmol/L (Table 1). More impor-
tantly, the target compounds 1a (derived from ciproﬂoxacin
2a) and 1p (derived from ciproﬂoxacin 2a and levoﬂoxacin 6c)
exhibit the most potent activity against HL60 cells. This
preliminary indication of antitumor activity suggests that di-
(1-cyclopropyl)-substituted ﬂuoroquinolones and bis-ﬂuoro-
quinolone hybrid molecules are promising lead compounds for
further development.3. Experimental procedures
3.1. Chemistry
Melting points were determined in sealed capillary tubes and
are uncorrected. IR spectra were recorded on a Nicolet Impact
410 spectrometer; 1H NMR spectra on a Bruker AM-400
spectrometer; mass spectra on an Esquire LC instrument and
elemental analyses on a PE2400-II instrument. The materials
and solvents were commercially available and used as received.3.1.1. General synthetic procedures for 1-cyclopropyl-6-
ﬂuoro-3-(5-mercapto-1,3,4-oxadiazol-2-yl)-7-substituted
piperazin-1-yl-quinolin-4 (1H)-one (4a–4c)
To a solution of hydrazide 3a–3c (58.0 mmol) in 95% EtOH
(500 mL) containing KOH (5.0 g, 90 mmol), carbon disulﬁde
was added at room temperature (7.0 g, 92 mmol) and the
mixture was stirred overnight. The resultant precipitate was
dissolved under reﬂuxing conditions. After removal of the
solvent under reduced pressure, a 3% aqueous NaOH solution
(500 mL) was added to the residue and reﬂuxed for 6 h. The
ﬁltrate was adjusted to pH 7.0 using concentrated HCl and the
resulting precipitate was collected and recrystallized from
DMF–EtOH to give yellow crystals 4a–4c.
1-Cyclopropyl-6-ﬂuoro-3-(5-mercapto-1,3,4-oxadiazol-2-yl)-
7-piperazin-1-yl-quinolin-4 (1H)-one 4a: yield 64%, mp
4250 1C; 1H NMR (DMSO-d6, 400 MHz) d: 13.64 (s, 1H,
SH), 8.87 (s, 1H, H-2), 7.72 (d, J¼13.2 Hz, 1H, 5-H), 7.62 (d,
J¼7.2 Hz, 1H, 8-H), 4.63–4.52 (m, 1H, CH), 3.56–3.32 (m, 8H,
piperazine-H), 1.26–1.14 (m, 4H, CH2CH2); IR (KBr) n: 3356,
3104, 2952, 1638, 1617, 1457 cm1; MS m/z: 388 [MþH]þ,
calcd. 387.44 [M]þ. Anal. calcd. for C18H18FN5O2: C 55.80,
H 4.68, N 18.08; found C 56.04, H 4.42, N 18.34.
1-Cyclopropyl-6-ﬂuoro-3-(5-mercapto-1,3,4-oxadiazol-2-yl)-
7-(4-methylpiperazin-1-yl)-quinolin-4 (1H)-one 4b: yield 72%,
mp4250 1C; 1H NMR (DMSO-d6, 400 MHz) d: 13.72 (s, 1H,
SH), 8.88 (s, 1H, H-2), 7.76 (d, J¼13.2 Hz, 1H, 5-H), 7.68 (d,
J¼7.2 Hz, 1H, 8-H), 4.62–4.55 (m, 1H, CH), 3.55–3.28 (m, 8H,
piperazine-H), 2.36 (s, 3H, CH3), 1.38–1.17 (m, 4H, CH2CH2);
IR (KBr) n: 3364, 3087, 2874, 1644, 1625, 1456 cm1; MS m/z:
402 [MþH]þ, calcd. 401.47 [M]þ. Anal. calcd. for
C19H20FN5O2: C 56.84, H 5.02, N 17.44; found C 57.11,
H 4.87, N 17.65.
1-Cyclopropyl-6-ﬂuoro-3-(5-mercapto-1,3,4-oxadiazol-2-yl)-
7-(4-ethylpiperazin-1-yl-quinolin-4 (1H)-one 4c: yield 68%,
mp4250 1C; 1H NMR (DMSO-d6, 400 MHz) d: 13.68
(s, 1H, SH), 8.84 (s, 1H, H-2), 7.82 (d, J¼13.2 Hz, 1H, 5-H),
7.64 (d, J¼7.2 Hz, 1H, 8-H), 4.64–4.52 (m, 1H, CH), 3.53–3.25
(m, 8H, piperazine-H), 2.37 (s, 3H, CH2), 1.42–1.15 (m, 7H,
CH2CH2 and CH3); IR (KBr) n: 3357, 3084, 2915, 1642, 1624,
1455 cm1; MS m/z: 416 [MþH]þ, calcd. 415.49 [M]þ. Anal.
calcd. for C20H22FN5O2: C 57.82, H 5.34, N 16.86; found
C 57.69, H 5.13, N 17.06.3.1.2. General synthetic procedures for 3-(4-amino-5-
mercapto-4H-1,2,4-triazol-3-yl)-1-cyclopropyl-6-ﬂuoro-7-
substituted piperazin-1-yl-quinolin-4 (1H)-one (5a–5c)
A mixture of 4a–4c (30.0 mmol), 85% hydrazine hydrate
(50 mL) and 30% aqueous NaOH solution (5.0 g, 125 mmol)
was stirred and reﬂuxed for 12 h. After removal of the solvent
under reduced pressure, the residue was dissolved in water
(500 mL) and treated by the same procedure as for 4 to give
the intermediate 5a–5c.
3-(4-Amino-5-mercapto-4H-1,2,4-triazol-3-yl)-1-cyclopro-
pyl-6-ﬂuoro-7-piperazin-1-yl-quinolin-4 (1H)-one 5a: yield
58%, mp 246–248 1C; 1H NMR (DMSO-d6, 400 MHz) d:
13.87 (s, 1H, SH), 8.96 (s, 1H, H-2), 8.14 (d, J¼13.2 Hz, 1H,
5-H), 7.85 (d, J¼7.2 Hz, 1H, 8-H), 5.86 (s, 2H, NH2), 4.66–
4.50 (m, 1H, CH), 3.55–3.34 (m, 8H, piperazine-H), 1.17–1.26
(m, 4H, CH2CH2); IR (KBr) n: 3442, 3008, 2867, 1630, 1616,
1457 cm1; MS m/z: 402 [MþH]þ, calcd. 401.47 [M]þ. Anal.
Design, synthesis and antitumor activity of C3/C3 bis-ﬂuoroquonolones cross-linked with triazolothiadiazole 175calcd. for C18H20FN7OS: C 53.85, H 5.02, N 24.42; found
C 53.96, H 4.84, N 24.68.
3-(4-Amino-5-mercapto-4H-1,2,4-triazol-3-yl)-1-cyclopro-
pyl-6-ﬂuoro-7-(4-methyl- piperazin-1-yl)-quinolin-4 (1H)-one
5b: yield 66%, mp 242-244 1C; 1H NMR (DMSO-d6,
400 MHz) d: 13.82 (s, 1H, SH), 9.05 (s, 1H, H-2), 8.21 (d,
J¼13.2 Hz, 1H, 5-H), 7.82 (d, J¼7.2 Hz, 1H, 8-H), 5.80 (s,
2H, NH2), 4.63–4.52 (m, 1H, CH), 3.52–3.32 (m, 8H, piper-
azine-H), 2.42 (s, 3H, CH3), 1.35–1.20 (m, 4H, CH2CH2); IR
(KBr) n: 3356, 3024, 2876, 1632, 1618, 1455 cm1; MS m/z:
416 [MþH]þ, calcd. 415.50 [M]þ. Anal. calcd. for
C19H22FN7OS: C 54.93, H 5.34, N 23.60; found C 55.17, H
5.11, N 23.85.
3-(4-Amino-5-mercapto-4H-1,2,4-triazol-3-yl)-1-cyclopro-
pyl-6-ﬂuoro-7-(4-ethyl- piperazin-1-yl)-quinolin-4 (1H)-one 5c:
yield 58%, mp 240–242 1C; 1H NMR (DMSO-d6, 400 MHz) d:
13.68 (s, 1H, SH), 9.07 (s, 1H, H-2), 8.16 (d, J¼13.2 Hz, 1H,
5-H), 7.80 (d, J¼7.2 Hz, 1H, 8-H), 5.76 (s, 2H, NH2), 4.62–
4.55 (m, 1H, CH), 3.52–3.34 (m, 8H, piperazine-H), 2.40 (s,
2H, CH2), 1.42–1.22 (m, 7H, CH2CH2 and CH3); IR (KBr) n:
3368, 3016, 2938, 1640, 1625, 1457 cm1; MS m/z: 430
[MþH]þ, calcd. 429.52 [M]þ. Anal. calcd. for C20H24FN7OS:
C 55.93, H 5.63, N 22.83; found C 56.15, H 5.40, N 23.07.3.1.3. Synthetic procedures for 1,2,4-Triazolo[3,4-
b][1,3,4]thiadiazole-3,6-bis-[1-cyclopropyl-6-ﬂuoro-7-
piperazin-1-yl-quinolin-4(1H)-one] dihydrochloride
(1a . 2HCl)
A mixture of 5a (1.0 g, 2.5 mmol), Ciproﬂoxacin 2a (1.0 g,
3.0 mmol) and 4-dimethylpyridine (DMAP) (0.4 g, 3.0 mmol)
in POCl3 (10 mL) was stirred at room temperature for 6 h and
then reﬂuxed for 3 h. The reaction mixture was concentrated
under reduced pressure, poured into ice-water (100 mL) and
adjusted to pH 10.0 with 30% aqueous NaOH solution. The
resulting precipitate was collected by ﬁltration and washed
with water to give the crude free base 1a, which was
recrystallized from 95% EtOH (30 mL) and concentrated
HCl (1.0 mL) to give a yellow solid 1a  2HCl: yield 32.0%,
mp 264 1C (dec.). 1H NMR (DMSO-d6, 400 MHz) d: 11.52
(br, 2H, 2HCl), 9.12–8.97 (br, 2H, 2 2-H), 7.84–7.78 (brs,
2H, 2 8-H), 7.63–7.55 (brs, 2H, 2 5-H), 4.66–4.47 (m, 2H,
2CH), 3.55–3.26 (m, 16H, 2 piperazine-H), 1.20–1.40 (m,
8H, 2CH2CH2); IR (KBr) n: 3356, 3054, 2947, 1633, 1616,
1552, 1442, 1338 cm1; MS m/z: 697 [MþH]þ, calcd. 696.79
[M]þ. Anal. calcd. for C35H34F2N10O2S  2HCl: C 54.62, H
4.71, N 18.20; found C 54.93, H 4.57, N 18.46.3.1.4. Synthetic procedure for the compounds
(1b–1r)  2HCl
By a procedure similar to that for 1a  2HCl, the compounds
(1b–1r)  2HCl were prepared. 1,2,4-Triazolo[3,4-b] [1,3.4]thiadia-
zole-3-[1-cyclopropyl-6-ﬂuoro-7-piperazin-1-yl-quinolin-4(1H)-
one]-6-[1-cyclopropyl-6-ﬂuoro-7-(4-methylpiperazin-1-yl)-qui-
nolin-4(1H)-one] dihydrochloride (1b  2HCl) derived from 5a
and N-Methylciproﬂoxacin 2b: yield 32%, mp 257 1C (dec.).
1H NMR (DMSO-d6, 400 MHz) d: 11.53 (br, 2H, 2HCl), 9.22–
9.15 (br, 2H, 2 2-H), 8.12–7.83 (br, 2H, 2 8-H), 7.65–7.53
(br, 2H, 2 5-H), 4.62–5.16 (m, 2H, 2CH), 3.53–3.24 (m,
16H, 2 piperazine-H), 2.40 (s, 3H, CH3) 1.41–1.22 (m, 8H,
2CH2CH2); IR (KBr) n: 3352, 3032, 2884, 1645, 1627, 1560,
1453, 1324 cm1; MS m/z: 711 [MþH]þ, calcd. 712.81 [M]þ;Anal. calcd. for C36H36F2N10O2S  2HCl: C 55.17, H 4.89, N
17.87; found C 55.34, H 4.68, N 18.07.
1,2,4-Triazolo[3,4-b][1,3,4]thiadiazole-3-[1-cyclopropyl-6-
ﬂuoro-7-piperazin-1-yl-quinolin-4(1H)-one]-6-[1-cyclopropyl-
6-ﬂuoro-7-(4-ethylpiperazin-1-yl)-quinolin-4(1H)-one] dihy-
drochloride (1c  2HCl) derived from 5a and Enroﬂoxacin 2c:
yield 28%, mp 255 1C (dec.). 1H NMR (DMSO-d6, 400 MHz)
d: 11.36 (br, 2H, 2HCl), 9.25–9.17 (br, 2H, 2 2-H), 7.88–7.72
(br, 2H, 2 8-H), 7.62–7.50 (br, 2H, 2 5-H), 4.60–4.44 (m,
2H, 2CH), 3.52–3.38 (m, 16H, 2 piperazine-H), 2.34 (q,
J¼6.5 Hz, 2H, N-CH2), 1.17–1.44 (m, 11H, 2CH2CH2 and
CH3); IR (KBr) n: 3368, 3027, 2876, 1642, 1608, 1562, 1457,
1226 cm1; MS m/z (%): 725 [MþH]þ, calcd. 724.84 [M]þ;
Anal. calcd. for C37H38F2N10O2S  2HCl: C 55.71, H 5.05, N
17.56; found C 55.93, H 5.30, N 17.82.
1,2,4-Triazolo[3,4-b][1,3,4]thiadiazole-3-[1-cyclopropyl-6-
ﬂuoro-7-piperazin-1-yl-quinolin-4(1H)-one]-6-[1-ethyl-6-
ﬂuoro-7-piperazin-1-yl)-quinolin-4(1H)-one] dihydrochloride
(1d  2HCl) derived from 5a and Norﬂoxacin 6a: yield 34%,
mp 240 1C (dec.). 1H NMR (DMSO-d6, 400 MHz) d: 11.46
(br, 2H, 2HCl), 9.04–8.87 (br, 2H, 2 2-H), 8.15–7.87 (br, 2H,
2 8-H), 7.62–7.55 (br, 2H, 2 5-H), 4.67–4.56 (m, 3H, N-
CH2 and CH), 3.55–3.27 (m, 16H, 2 piperazine-H), 1.46–
1.22 (m, 7H, CH2CH2 and CH3); IR (KBr) n: 3364, 3025,
2896, 1642, 1627, 1562, 1455, 1226 cm1; MS m/z: 685
[MþH]þ, calcd. 684.78 [M]þ. Anal. calcd. for
C34H34F2N10O2S  2HCl: C 53.90, H 4.79, N 18.49; found C
54.13, H 4.58, N 18.67.
1,2,4-Triazolo[3,4-b][1,3,4]thiadiazole-3-[1-cyclopropyl-6-
ﬂuoro-7-(4-methylpiperazin-1-yl)-quinolin-4(1H)-one]-6-(1-
cyclopropyl-6-ﬂuoro-7-piperazin-1-yl-quinolin-4(1H)-one)
dihydrochloride (1e  2HCl) derived from 5b and Ciproﬂoxacin
2a, yield 27.0%, mp 256 1C (dec.). 1H NMR (DMSO-d6,
400 MHz) d: 11.42 (br, 2H, 2HCl), 9.17–8.92 (br, 2H, 2 2-
H), 7.82–7.76 (brs, 2H, 2 8-H), 7.62–7.58 (brs, 2H, 2 5-H),
4.63–5.24 (m, 2H, 2CH), 3.50–3.24 (m, 16H, 2 piperazine-
H), 2.42 (s, 3H, CH3), 1.42–1.23 (m, 8H, 2CH2CH2); IR
(KBr) n: 3347, 3054, 2962, 1638, 1624, 1557, 1445 cm1; MS
m/z: 711 [MþH]þ, calcd. 710.81 [M]þ. Anal. calcd. for
C36H36F2N10O2S  2HCl: C 55.17, H 4.89, N 17.87; found C
55.42, H 4.66, N 18.72.
1,2,4-Triazolo[3,4-b][1,3,4]thiadiazole-3,6-bis-[1-cyclopro-
pyl-6-ﬂuoro-7-(4-methyl-piperazin-1-yl)-quinolin-4(1H)-one]
dihydrochloride (1f  2HCl) derived from 5b and N-Methylci-
proﬂoxacin 2b: yield 25%, mp 253 1C (dec.). 1H NMR
(DMSO-d6, 400 MHz) d: 11.62 (br, 2H, 2HCl), 9.15–9.08
(br, 2H, 2 2-H), 8.14–7.80 (br, 2H, 2 8-H), 7.72–7.56 (br,
2H, 2 5-H), 4.62–4.47 (m, 2H, 2CH), 3.50–3.27 (m, 16H,
2 piperazine-H), 2.37–2.44 (brs, 6H, 2CH3), 1.40–1.22 (m,
8H, 2CH2CH2); IR (KBr) n: 3364, 3015, 2893, 1642, 1624,
1557, 1455, 1276 cm1; MS m/z: 725 [MþH]þ, calcd. 724.84
[M]þ. Anal. calcd. for C37H38F2N10O2S  2HCl: C 55.71, H
5.05, N 17.56; found C 55.94, H 4.87, N 17.80.
1,2,4-Triazolo[3,4-b][1,3,4]thiadiazole-3-[1-cyclopropyl-6-ﬂuoro-
7-(4-methylpiperazin-1-yl)-quinolin-4(1H)-one]-6-[1-cyclopropyl-6-
ﬂuoro-7-(4-ethylpiperazin-1-yl)-quinolin-4(1H)-one] dihydrochlor-
ide (1g  2HCl) derived from 5b and Enroﬂoxacin 2c: yield 31%,
mp 252 1C (dec.). 1H NMR (DMSO-d6, 400 MHz) d: 11.35 (br,
2H, 2HCl), 9.22–9.13 (br, 2H, 2 2-H), 7.86–7.75(br, 2H, 2 8-
H), 7.64–7.57 (br, 2H, 2 5-H), 4.62–4.50 (m, 2H, 2CH), 3.57–
3.35 (m, 16H, 2 piperazine-H), 2.40–2.34 (m, 5H, CH3 and
CH2), 1.45–1.18 (m, 11H, 2CH2CH2 and CH3); IR (KBr)
Guo-qiang Hu et al.176n: 3347, 3006, 2876, 1644, 1616, 1563, 1457, 1247 cm1; MS m/z
(%): 739 [MþH]þ, calcd. 738.87 [M]þ. Anal. calcd. for
C38H40F2N10O2S  2HCl: C 56.22, H 5.21, N 17.25; found C
55.45, H 5.37, N 17.46.
1,2,4-Triazolo[3,4-b][1,3,4]thiadiazole-3-[1-cyclopropyl-6-
ﬂuoro-7-(4-methylpiperazin-1-yl)-quinolin-4(1H)-one]-6-[1-
ethyl-6-ﬂuoro-7-piperazin-1-yl)-quinolin-4(1H)-one] dihy-
drochloride (1h  2HCl) derived from 5b and Norﬂoxacin 6a:
yield 25%, mp 242 1C (dec.). 1H NMR (DMSO-d6, 400 MHz)
d: 11.44 (br, 2H, 2HCl), 9.06–8.89 (br, 2H, 2 2-H), 8.17–7.84
(br, 2H, 2 8-H), 7.66–7.57 (br, 2H, 2 5-H), 4.60–4.57 (m,
3H, CH2 and CH), 3.50–3.25 (m, 16H, 2 piperazine-H),
1.44–1.20 (m, 7H, CH2CH2 and CH3); IR (KBr) n: 3372, 3045,
1644, 1626, 1572, 1457, 1238 cm1; MS m/z: 699 [MþH]þ,
calcd. 698.80 [M]þ. Anal. calcd. for C35H36F2N10O2S  2HCl:
C 54.47, H 4.96, N 18.15; found C 54.68, H 4.72, N 18.36.
1,2,4-Triazolo[3,4-b][1,3,4]thiadiazole-3-[1-cyclopropyl-6-
ﬂuoro-7-(4-ethylpiperazin-1-yl)-quinolin-4(1H)-one]-6-(1-
cyclopropyl-6-ﬂuoro-7-piperazin-1-yl-quinolin-4(1H)-one)
dihydrochloride (1i  2HCl) derived from 5c and Ciproﬂoxacin
2a: yield 24.0%, mp 251 1C (dec.). 1H NMR (DMSO-d6,
400 MHz) d: 11.62 (br, 2H, 2HCl), 9.22–8.94 (br, 2H, 2 2-
H), 7.86–7.75 (brs, 2H, 2 8-H), 7.68–7.54 (brs, 2H, 2 5-H),
4.68–5.42 (m, 2H, 2CH), 3.54–3.18 (m, 16H, 2 piperazine-
H), 2.46–2.37 (brs, 5H, CH2 and CH3), 1.45–1.22 (m, 11H,
CH3 and 2CH2CH2); IR (KBr) n: 3367, 3038, 2967, 1636,
1628, 1557, 1452 cm1; MS m/z: 725 [MþH]þ, calcd. 724.84
[M]þ. Anal. calcd. for C37H38F2N10O2S  2HCl: C 55.71, H
5.05, N 17.56; found C 55.92, H 4.87, N 17.83.
1,2,4-Triazolo[3,4-b][1,3,4]thiadiazole-3-[1-cyclopropyl-6-ﬂuoro-
7-(4-ethylpiperazin-1-yl)-quinolin-4(1H)-one]-6-[1-cyclopropyl-6-
ﬂuoro-7-(4-methylpiperazin-1-yl)-quinolin-4(1H)-one] dihydroch-
loride (1j  2HCl) derived from 5c and N-Methylciproﬂoxacin 2b:
yield 22%, mp 248 1C (dec.). 1H NMR (DMSO-d6, 400 MHz) d:
11.70 (br, 2H, 2HCl), 9.18–9.04 (br, 2H, 2 2-H), 8.20–7.86 (br,
2H, 2 8-H), 7.75–7.62 (br, 2H, 2 5-H), 4.68–5.36 (m, 2H,
2CH), 3.52–3.30 (m, 16H, 2 piperazine-H), 2.41–2.45 (brs,
5H, CH2 and CH3), 1.42–1.20 (m, 11H, 2CH2CH2); IR (KBr)
n: 3358, 3034, 2884, 1638, 1622, 1557, 1453, 1262 cm1; MS m/z:
739 [MþH]þ, calcd. 738.87 [M]þ. Anal. calcd. for C38H40F2N10
O2S  2HCl: C 56.22, H 5.21, N 17.25; found C 56.45, H 5.02,
N 17.46.
1,2,4-Triazolo[3,4-b][1,3,4]thiadiazole-3,6-bis-[1-cyclopro-
pyl-6-ﬂuoro-7-(4-ethyl-piperazin-1-yl)-quinolin-4(1H)-one]
dihydrochloride (1k  2HCl) derived from 5c and Enroﬂoxacin
2c: yield 20%, mp 246 1C (dec.). 1H NMR (DMSO-d6,
400 MHz) d: 11.42 (br, 2H, 2HCl), 9.24–9.15 (br, 2H, 2 2-
H), 7.84–7.72 (br, 2H, 2 8-H), 7.68–7.52 (br, 2H, 2 5-H),
4.66–4.53 (m, 2H, 2CH), 3.55–3.34 (m, 16H, 2 piperazine-
H), 2.45–2.42 (m, 4H, 2CH2), 1.46–1.17 (m, 14H,
2CH2CH2 and 2CH3); IR (KBr) n: 3363, 3027, 2885,
1640, 1626, 1568, 1454, 1238 cm1; MS m/z (%): 753 [MþH]þ,
calcd. 752.90 [M]þ. Anal. calcd. for C39H42F2N10O2S  2HCl:
C 56.72, H 5.37, N 16.96; found C 56.87, H 5.11, N 17.16.
1,2,4-Triazolo[3,4-b][1,3,4]thiadiazole-3-[1-cyclopropyl-6-ﬂuoro-
7-(4-ethylpiperazin-1-yl)-quinolin-4(1H)-one]-6-[1-ethyl-6-ﬂuoro-7-
piperazin-1-yl)-quinolin-4(1H)-one] dihydrochloride (1l  2HCl)
derived from 5c and Norﬂoxacin 6a: yield 23%, mp 238 1C
(dec.). 1H NMR (DMSO-d6, 400 MHz) d: 11.64 (br, 2H, 2HCl),
9.12–8.93 (br, 2H, 2 2-H), 8.22–7.86 (br, 2H, 2 8-H), 7.72–7.63
(br, 2H, 2 5-H), 4.64–4.53 (m, 3H, CH2 and CH), 3.56–3.27
(m, 16H, 2 piperazine-H), 1.46–1.25 (m, 10H, CH2CH2 and2CH3); IR (KBr) n: 3366, 3035, 1628, 1617, 1557, 1456,
1228 cm1; MS m/z: 725 [MþH]þ, calcd. 724.84 [M]þ. Anal.
calcd. for C37H38F2N10O2S  2HCl: C 55.71, H 5.05, N 17.56;
found C 55.90, H 4.88, N 17.84.
(S,R)-1,2,4-Triazolo[3,4-b][1,3,4]thiadiazole-3-[1-cyclopro-
pyl-6-ﬂuoro-7-piperazin-1-yl-quinolin-4(1H)-one]-6-[1,8-(2,1-
oxypropyl)-6-ﬂuoro-7-(4-methylpiperazin-1-yl)-quinolin-
4(1H)-one] dihydrochloride (1m  2HCl) derived from 5a and
Oﬂoxacin 6b: yield 36%, mp 238–240 1C (dec.). 1H NMR
(DMSO-d6, 400 MHz) d: 11.38 (br, 2H, 2HCl), 9.16–8.94 (br,
2H, 2 2-H), 7.86 (d, J¼2.4 Hz, 1H, 8-H), 7.62–7.55 (br, 2H,
2 5-H), 4.57–4.45 (m, 4H, OCH2CHN and CH), 3.53–3.36
(m, 16H, 2 piperazine-H), 2.46 (s, 3H, N-CH3), 1.16–1.44
(m, 7H, CH2CH2 and CH3); IR (KBr) n: 3356, 3032, 2892,
1638, 1604, 1567, 1457, 1228 cm1; MS m/z: 727 [MþH]þ,
calcd. 726.81 [M]þ. Anal. calcd. for C36H36F2N10O3S  2HCl:
C 54.07, H 4.79, N 17.51; found C 54.26, H 4.60, N 17.72.
(S,R)-1,2,4-Triazolo[3,4-b][1,3,4]thiadiazole-3-[1-cyclopropyl-
6-ﬂuoro-7-(4-methyl-piperazin-yl)-quinolin-4(1H)-one]-6-[1,8-
(2,1-oxypropyl)-6-ﬂuoro-7-(4-methylpiperazin-1-yl)-quinolin-
4(1H)-one] dihydrochloride (1n  2HCl) derived from 5b and
Oﬂoxacin 6b: yield 31%, mp 235 1C (dec.). 1H NMR (DMSO-
d6, 400 MHz) d: 11.50 (br, 2H, 2HCl), 9.18–8.97 (br, 2H, 2 2-
H), 7.85 (d, J¼2.4 Hz, 1H, 8-H), 7.65–7.58 (br, 2H, 2 5-H),
4.62–4.50 (m, 4H, OCH2CHN and CH), 3.56–3.34 (m, 16H,
2piperazine-H), 2.48–2.43 (m, 6H, 2CH3), 1.46–1.20 (m,
7H, CH2CH2 and CH3); IR (KBr) n: 3358, 3027, 2918, 1632,
1615, 1557, 1455, 1236 cm1; MS m/z: 741 [MþH]þ, calcd.
740.84 [M]þ. Anal. calcd. for C37H38F2N10O3S  2HCl: C 54.61,
H 4.95, N 17.21; found C 54.82, H 4.67, N 17.46.
(S,R)-1,2,4-Triazolo[3,4-b][1,3,4]thiadiazole-3-[1-cyclopro-
pyl-6-ﬂuoro-7-(4-ethyl-piperazin-yl)-quinolin-4(1H)-one]-6-
[1,8-(2,1-oxypropyl)-6-ﬂuoro-7-(4-methylpiperazin-1-yl)-quino-
lin-4(1H)-one] dihydrochloride (1o  2HCl) derived from 5c and
Oﬂoxacin 6b: yield 23%, mp 234 1C (dec.). 1H NMR (DMSO-
d6, 400 MHz) d: 11.52 (br, 2H, 2HCl), 9.18–8.95 (br, 2H, 2 2-
H), 7.86 (d, J¼2.4 Hz, 1H, 8-H), 7.72–7.56 (br, 2H, 2 5-H),
4.66–4.52 (m, 4H, OCH2CHN and CH), 3.57–3.35 (m, 16H,
2 piperazine-H), 2.46–2.40 (m, 5H, CH2 and CH3), 1.48–1.18
(m, 10H, CH2CH2 and 2CH3); IR (KBr) n: 3366, 3025, 2936,
1636, 1622, 1558, 1455, 1228 cm1; MS m/z: 755 [MþH]þ,
calcd. 754.87 [M]þ. Anal. calcd. for C38H40F2N10O3S  2HCl: C
55.14, H 5.11, N 16.92; found C 55.38, H 5.34, N 17.11.
(S)-1,2,4-Triazolo[3,4-b][1,3,4]thiadiazole-3-[1-cyclopropyl-
6-ﬂuoro-7-piperazin-1-yl-quinolin-4(1H)-one]-6-[1,8-(2,1-oxy-
propyl)-6-ﬂuoro-7-(4-methylpiperazin-1-yl)-quinolin-4(1H)-
one] dihydrochloride (1p  2HCl) derived from 5a and Levo-
ﬂoxacin 6c: yield 26%, mp 224–226 1C (dec.). 1H NMR
(DMSO-d6, 400 MHz) d: 11.26 (br, 2H, 2HCl), 9.17–8.96
(br, 2H, 2 2-H), 7.88 (d, J¼2.4 Hz, 1H, 8-H), 7.64–7.57
(br, 2H, 2 5-H), 4.56–4.47 (m, 4H, OCH2CHN and CH),
3.55–3.37 (m, 16H, 2 piperazine-H), 2.42 (s, 3H, N-CH3),
1.18–1.46 (m, 7H, CH2CH2 and CH3); IR (KBr) n: 3364, 3036,
2895, 1642, 1608, 1564, 1455, 1226 cm1; MS m/z (%): 727
[MþH]þ, calcd. 726.81 [M]þ. Anal. calcd. for
C36H36F2N10O3S  2HCl: C 54.07, H 4.79, N 17.51; found C
54.28, H 4.64, N 17.6.
(S)-1,2,4-Triazolo[3,4-b][1,3,4]thiadiazole-3-[1-cyclopropyl-
6-ﬂuoro-7-(4-methyl- piperazin-yl)-quinolin-4(1H)-one]-6-[1,8-
(2,1-oxypropyl)-6-ﬂuoro-7-(4-methylpiperazin-1-yl)-quinolin-
4(1H)-one] dihydrochloride (1q  2HCl) derived from 5b and
Levoﬂoxacin 6c: yield 25%, mp 220 1C (dec.). 1H NMR
Design, synthesis and antitumor activity of C3/C3 bis-ﬂuoroquonolones cross-linked with triazolothiadiazole 177(DMSO-d6, 400 MHz) d: 11.62 (br, 2H, 2HCl), 9.22–8.98 (br,
2H, 2 2-H), 7.86 (d, J¼2.4 Hz, 1H, 8-H), 7.64–7.52 (br, 2H,
2 5-H), 4.64–4.53 (m, 4H, OCH2CHN and CH), 3.53–3.32
(m, 16H, 2 piperazine-H), 2.46–2.40 (m, 6H, 2CH3), 1.45–
1.17 (m, 7H, CH2CH2 and CH3); IR (KBr) n: 3363, 3025,
2925, 1634, 1618, 1557, 1456, 1234 cm1; MS
m/z: 741 [MþH]þ, calcd. 740.84 [M]þ. Anal. calcd. for
C37H38F2N10O3S  2HCl: C 54.61, H 4.95, N 17.21; found
C 54.77, H 4.75, N 17.42.
(S)-1,2,4-Triazolo[3,4-b][1,3,4]thiadiazole-3-[1-cyclopropyl-
6-ﬂuoro-7-(4-ethyl- piperazin-yl)-quinolin-4(1H)-one]-6-[1,8-
(2,1-oxypropyl)-6-ﬂuoro-7-(4-methylpiperazin-1-yl)-quinolin-
4(1H)-one] dihydrochloride (1r  2HCl) derived from 5c and
Levoﬂoxacin 6c: yield 20%, mp 216 1C (dec.). 1H NMR
(DMSO-d6, 400 MHz) d: 11.50 (br, 2H, 2HCl), 9.17–8.96
(br, 2H, 2 2-H), 7.88 (d, J¼2.4 Hz, 1H, 8-H), 7.74–7.60
(br, 2H, 2 5-H), 4.66–4.50 (m, 4H, OCH2CHN and CH),
3.56–3.35 (m, 16H, 2 piperazine-H), 2.47–2.44 (m, 5H, CH2
and CH3), 1.48–1.20 (m, 10H, CH2CH2 and 2CH3); IR
(KBr) n: 3358, 3027, 2934, 1640, 1624, 1562, 1455, 1232 cm1;
MS m/z: 755 [MþH]þ, calcd. 754.87 [M]þ. Anal. calcd. for
C38H40F2N10O3S  2HCl: C 55.14, H 5.11, N 16.92; found C
55.36, H 5.28, N 17.14.
3.2. MTT assay
The tumor cell lines, L1210, HL60 and CHO, were maintained
in RPMI 1640 medium supplemented with 10% heat-inacti-
vated fetal bovine serum. Medium containing 5 103 cells was
seeded into each well of a 96-well microplate and solutions of
test compounds at concentrations of 0.1, 1.0, 10.0, 30.0 and
50.0 mmol/L added simultaneously to triplicate wells before
making the ﬁnal volume up to 100 mL. Plates were incubated at
37 1C for 48 h in a humidiﬁed atmosphere (5% CO2, 95% air)
after which 100 mL methylthiazole trazolium (MTT) solution
(1.0 mg/mL in phosphate-buffered saline lacking calcium and
magnesium) was added to each well. After a further incubation
for 4 h at 37 1C, 100 mL DMSO was added to CHO cells and
10% sodium dodecylbenzene sulfonate (SDS) added to L1210
and HL60 cells to solubilize any MTT-formazan produced.
The optical density (OD) of each well was measured at 570 nm
(OD570) with a microplate reader and the inhibition of cell
growth (%) was calculated as (1T/C) 100, where C is the
mean OD570 of the control group and T is that of the treated
group. The IC50 was determined from the concentration–
response data.Acknowledgment
Project supported by the National Natural Science Founda-
tion of China (nos. 20872028, 21072045).
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